Daniel D. Burgess, Director at Nabriva Therapeutics plc (NBRV), bought 36,000 shares at $2.75 ($99K) on 2018-07-31, disclosed to the SEC on 2018-08-02.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| CDTX | BUY | 2015-04-21 | $48K | — | Filing → |
| SNTS | SELL | 2013-06-04 | $171K | — | Filing → |
| SNTS | SELL | 2013-05-02 | $143K | — | Filing → |